Beta-amyloid oligomers: Recent developments

Biomolecular Concepts

Volumn 2, Issue 3, 2011, Pages 211-222

  Borutaite, Vilmante ^a   Morkuniene, Ramune ^a   Valincius, Gintaras ^b  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^b VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Alzheimer's disease; neuronal cell death; amyloid

Indexed keywords

EID: 84868337376     PISSN: 18685021     EISSN: 1868503X     Source Type: Journal    
DOI: 10.1515/bmc.2011.019     Document Type: Review

References (135)

1. Glabe CG. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 2006; 27: 570-5
2. Walsh DM, Selkoe DJ. A b oligomers-A decade of discovery. J Neurochem 2007; 101: 1172-84
3. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-6
4. Zhang Y, Thompson R, Zhang H, Xu H. APP processing in Alzheimer's disease. Mol Brain 2011; 4: 3
5. Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, Yates J, Cotman C, Glabe C. Assembly and aggregation properties of synthetic Alzheimer's A4/b amyloid peptide analogs. J Biol Chem 1992; 267: 546-54
6. Harper JD, Lansbury PT Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Proc Natl Acad Sci USA 2003; 100: 330-5
7. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid beta-protein (Abeta) assembly: Ab 40 and Ab 42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 2002; 100: 330-5
8. Lublin AL, Gandy S. Amyloid-b oligomers: possible roles as key neurotoxins in Alzheimer's disease. Mount Sinai J Med 2010; 77: 43-9
9. Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, Silberring J, Gandy SE, Winblad B, Greengard P, Nordstedt C, Terenius L. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA 1994; 91: 8378-82
10. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, McCormack R, Wolfert R, Selkoe D, Lieberburg I, Schenk D. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992; 359: 325-7
11. Xu H, Greengard P, Gandy S. Regulated formation of Golgi secretory vesicles containing Alzheimer-Amyloid precursor protein. J Biol Chem 1995; 270: 23243-5
12. Kinoshita A, Fukumoto H, Shah T, Whelan CM, Irizarry MC, Hyman BT. Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci 2003; 116: 3339-46
13. Mizuguchi M, Ikeda K, Kim SU. Differential distribution of cellular forms of b-Amyloid precursor protein in murine glial cell cultures. Brain Res 1992; 584: 219-25
14. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR. Intraneuronal A42 accumulation in human brain. Am J Pathol 2000; 156: 15-20
15. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. RAGE and amyloid-b peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 685-91
16. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Mannes L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. RAGE mediates amyloid-b peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9: 907-13
17. Yazawa H, Yu ZX, Takeda, Le Y, Gong W, Ferrans VJ, Oppenheim JJ, Li CC, Wang JM. Beta amyloid peptide (A42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. FASEB J 2001; 15: 2454-62
18. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-b in Alzheimer's disease. Nat Rev Neurosci 2007; 8: 499-509
19. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, Clarke EE, Zheng H, Van Der Ploeg LH, Ruffolo SC, Thornberry NA, Xanthoudakis S, Zamboni RJ, Roy S, Nicholson DW. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-b precursor protein and amyloidogenic Ab peptide formation. Cell 1999; 97: 395-406
20. Park SA, Shaked GM, Bredesen DE, Koo EH. Mechanism of cytotoxicity mediated by the C31 fragment of the amyloid precursor protein. Biochem Biophys Res Commun 2009; 388: 450-5
21. Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q(10) as a potential treatment. J Bioenerg Biomembr 2004; 36: 381-6
22. Zheng H, Koo EH. The amyloid precursor protein: beyond amyloid. Mol Neurodegener 2006; 1: 5
23. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, Selkoe DJ. Amyloid b-peptide is produced by cultured cells during normal metabolism. Nature 1992; 359: 322-5
24. Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA. The production of amyloid b peptide is a critical requirement for the viability of central neurons. J Neurosci 2003; 23: 5531-5
25. Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, Bruno V, Molinaro G, Pappalardo G, Messina A, Palmigiano A, Garozzo D, Nicoletti F, Rizzarelli E, Copani A. Beta-Amyloid monomers are neuroprotective. J Neurosci 2009; 29: 10582-7
26. Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, Palmeri A, Arancio O. Picomolar amyloid-b positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 2008; 28: 14537-45
27. Klein WL, Krafft GA, Finch CE. Targeting small Ab oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 2001; 24: 219-24
28. Welander H, Franberg J, Graff C, Sundstrom E, Winblad B, Tjernberg LO. A b 43 is more frequent than A beta 40 in amyloid plaque cores from Alzheimer disease brains. J Neurochem 2009; 110: 697-706
29. Lazo ND, Grant MA, Condron MC, Alan C, Rigby AC, Teplow DB. On the nucleation of amyloid-b protein monomer folding. Protein Sci 2005; 14: 1581-96
30. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Naslund J, Lannfelt L. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Ab protofibril formation. Nat Neurosci 2001; 4: 887-93
31. Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, Bots GTAM, Luyendijk W, Frangione B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch-Type. Science 1990; 248: 1124-6
32. Bugiani O, Padovani A, Magoni M, Andora G, Sgarzi M, Savoiardo M, Bizzi A, Giaccone G, Rossi G, Tagliavini F. An Italian type of HCHWA. Neurobiol Aging 1998; 19: S238
33. Cras P, van Harskamp F, Hendriks L, Ceuterick C, van Duijn CM, Stefanko SZ, Hofman A, Kros JM, Van Broeckhoven C, Martin JJ. Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692AlaGly mutation. Acta Neuropathol 1998; 96: 253-60
34. Grabowski TJ, Cho HS, Vonsattel JPG, Rebeck GW, Greenberg SM. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol 2001; 49: 697-705
35. Giaccone G, Morbin M, Moda F, Botta M, Mazzoleni G, Uggetti A, Catania M, Moro ML, Redaelli V, Spagnoli A, Rossi RS, Salmona M, Di Fede G, Tagliavini F. Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features. Acta Neuropathol 2010; 120: 803-12
36. Ono K, Condron MM, Teplow DB. Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid b-protein assembly and toxicity. J Biol Chem 2010; 285: 23184-95
37. Hori Y, Hashimoto T, Wakutani Y, Urakami K, Nakashima K, Condron MM, Tsubuki S, Saido TC, Teplow DB, Iwatsubo T. The Tottori (D7N) and English (H6R) familial Alzheimer disease mutations accelerate Ab fibril formation without increasing protofibril formation. J Biol Chem 2007; 282: 4916-23
38. Armstrong J, Boada M, Rey MJ, Vidal N, Ferrer I. Familial Alzheimer disease associated with A713T mutation in APP. Neurosci Lett 2004; 370: 241-3
39. Glabe CG. Structural classification of toxic amyloid oligomers. J Biol Chem 2008; 283: 29639-43
40. Rauk A. The chemistry of Alzheimer's disease. Chem Soc Rev 2009; 38: 2698-715
41. Miller Y, Ma BY, Nussinov R. Zinc ions promote Alzheimer Ab aggregation via population shift of polymorphic states. Proc Natl Acad Sci USA 2010; 107: 9490-5
42. Zhuang W, Sgourakis NG, Li ZY, Garcia AE, Mukamel S. Discriminating early stage Ab 42 monomer structures using chirality-induced 2DIR spectroscopy in a simulation study. Proc Natl Acad Sci USA 2010; 107: 15687-92
43. Tomaselli S, Esposito V, Vangone P, van Nuland NAJ, Bonvin AMJJ, Guerrini R, Tancredi T, Temussi PA, Picone D. The ato-b conformational transition of Alzheimer's A b-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding. Chem Biochem 2006; 7: 257-67
44. Sticht H, Bayer P, Willbold D, Dames S, Hilbich C, Beyreuther K, Frank RW, Rosch P. Structure of amyloid A-(1-40)-peptide of Alzheimer's disease. Eur J Biochem 1995; 233: 293-8
45. Chen YR, Huang HB, Chyan CL, Shiao MS, Lin TH, Chen YC. The effect of Ab conformation on the metal affinity and aggregation mechanism studied by circular dichroism spectroscopy. J Biochem 2006; 139: 733-40
46. Cizas P, Budvytyte R, Morkuniene R, Moldovan R, Broccio M, Lösche M, Niaura G, Valincius G, Borutaite V. Size-dependent neurotoxicity of b-Amyloid oligomers. Arch Biochem Biophys 2010; 496: 84-92
47. Yang C, Li JY, Li Y, Zhu XL. The effect of solvents on the conformations of Amyloid b-peptide (1-42) studied by molecular dynamics simulation. J Mol Struct Theochem 2009; 895: 1-8
48. Filippov AV, Grobner G, Antzutkin ON. Aggregation of amyloid A b(1-40) peptide in perdeuterated 2, 2, 2-Trifluoroethanol caused by ultrasound sonication. Magnetic Res Chem 2010; 48: 427-34
49. Wei GH, Shea JE. Effects of solvent on the structure of the Alzheimer amyloid-b (25-35) peptide. Biophys J 2006; 91: 1638-47
50. Kamiya N, Mitomo D, Shea JE, Higo J. Folding of the 25 residue Ab (12-36) peptide in TFE/water: temperature-dependent transition from a funneled free-energy landscape to a rugged one. J Phys Chem 2007; 111: 5351-6
51. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 2003; 26: 207-14
52. Exley C. Aluminium and iron, but neither copper nor zinc, are key to the precipitation of beta-sheets of A b(42) in senile plaque cores in Alzheimer's disease. J Alzh Dis 2006; 10: 173-7
53. Faller P, Hureau C. Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-b peptide. Dalton Transact 2009; 7: 1080-94
54. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, Tanzi RE, Bush AI. Characterization of copper interactions with Alzheimer Ab peptides-identification of an attomolar affinity copper binding site on Ab1-42. J Neurochem 2000; 75: 1219-33.
55. Tougu V, Karafin A, Palumaa P. Binding of zinc(II) and copper(II) to the full-length Alzheimer's amyloid-b peptide. J Neurochem 2008; 104: 1249-59
56. Nair NG, Perry G, Smith MA, Reddy VP. NMR studies of zinc, copper, and iron binding to histidine, the principal metal ion complexing site of amyloid-b peptide. J Alzh Dis 2010; 20: 57-66
57. Miura T, Suzuki K, Kohata N, Takeuchi H. Metal binding modes of Alzheimer's amyloid b-peptide in insoluble aggregates and soluble complexes. Biochem 2000; 39: 7024-31
58. Tsvetkov PO, Kulikova AA, Golovin AV, Tkachev YV, Archakov AI, Kozin SA, Makarov AA. Minimal Zn2q binding site of amyloid-b. Biophys J 2010; 99: L84-6
59. Minicozzi V, Stellato F, Comai M, Dalla Serra DS, Potrich C, Meyer-Klaucke W, Morante S. Identifying the minimal copperand zinc-binding site sequence in amyloid-peptides. J Biolog Chem 2008; 283: 10784-92
60. Shin B-K, Saxena S. Direct evidence that all three histidine residues coordinate to Cu(II) in amyloid-b1-16. Biochem 2008; 47: 9117-23
61. Lu Y, Prudent M, Qiao LA, Mendez MA, Girault HH. Copper(I) and copper(II) binding to b-Amyloid 16 (Ab16) studied by electrospray ionization mass spectrometry. Metallomics 2010; 2: 474-9
62. Balland V, Hureau C, Jean-Michel Savéant J-M. Electrochemical and homogeneous electron transfers to the Alzheimer amyloidb copper complex follow a preorganization mechanism. Proc Natl Acad Sci USA 2010; 107: 17113-8
63. Pramanik D, Dey SG. Active site environment of heme-bound amyloid b peptide associated with Alzheimer's disease. JACS 2011; 133: 81-7
64. Duce JA, Bush AI. Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics. Progress Neurobiol 2010; 92: 1-18
65. Faller P. Copper and zinc binding to amyloid-b: coordination, dynamics, aggregation, reactivity and metal-ion transfer. ChemBioChem 2009; 10: 2837-45
66. Bolognin S, Messori L, Zatta P. Metal ion physiopathology in neurodegenerative disorders. Neuromol Med 2009; 11: 223-38
67. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB. Amyloid bprotein assembly and Alzheimer disease. J Biol Chem 2009; 284: 4749-53
68. Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E, Hall J, Glabe C. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem 2009; 284: 4230-7
69. Kagan BL, Azimov R, Azimova R. Amyloid peptide channels. J Membr Biol 2004; 202: 1-10
70. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal long-Term potentiation in vivo. Nature 2002; 416: 535-9
71. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloidb protein induce reversible synapse loss by modulating an NMDA-Type glutamate receptor-dependent signaling pathway. J Neurosci 2007; 27: 2866-75
72. Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK. Oligomerization of Alzheimer's b-Amyloid within processes and synapses of cultured neurons and brain. J Neurosci 2004; 24: 3592-9
73. O'Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, Collinge J, Walsh DM. Amyloid b-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci 2010; 30: 14411-9
74. Lashuel HA, Hartley DM, Petre BM, Wall JS, Simon MN, Walz T, Lansbury PT. Mixtures of wild-Type and a pathogenic (E22G) form of Ab 40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol 2003; 332: 795-808
75. Melquiond A, Dong X, Mousseau N, Derreumaux P. Role of the region 23-28 in Ab fibril formation: insights from simulations of the monomers and dimers of Alzheimer's peptides Ab40 and Ab42. Curr Alzheimer Res 2008; 5: 244-50
76. Innocenti M, Salvietti E, Guidotti M, Casini A, Bellandi S, Foresti ML, Gabbiani C, Pozzi A, Zatta P, Messori L. Trace copper(II) or zinc(II) ions drastically modify the aggregation behavior of amyloid-b(1-42): an AFM study. J Alzh Dis 2010; 19: 1323-9
77. Yu L, Edalji R, Harlan JE, Holzman TF, Lopez AP, Labkovsky B, Hillen H, Barghorn S, Ebert U. Structural characterization of a soluble amyloid b-peptide oligomer. Biochemistry 2009; 48: 1870-7
78. Yang TT, Hsu CT, Kuo YM. Cell-derived soluble oligomers of human amyloid-b peptides disturb cellular homeostasis and induce apoptosis in primary hippocampal neurons. J Neural Transm 2009; 116: 1561-9
79. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-b protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-42
80. Reed MN, Hofmeister JJ, Jungbauer L, Welzel AT, Yu C, Sherman MA, Lesne S, LaDu MJ, Walsh DM, Ashe KH, Cleary JP. Cognitive effects of cell-derived and synthetically derived Ab oligomers. Neurobiol Aging In press. Available at http://www.sciencedirect.com/science/article/pii/S0197458009003674
81. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. Detection of intracellular oligomers of amyloid b-protein in cells derived from human brain. Biochem 2000; 39: 10831-9
82. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ. Amyloid b protein dimercontaining human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 2008; 28: 4231-7
83. Capone R, Quiroz FG, Prangkio P, Saluja I, Sauer AM, Bautista MR, Turner RS, Yang J, Mayer M. Amyloid-beta-induced ion flux in artificial lipid bilayers and neuronal cells: resolving a controversy. Neurotox Res 2009; 16: 1-13
84. Fezoui Y, Hartley DM, Harper JD, Khurana R, Walsh DM, Condron MM, Selkoe DJ, Lansbury PT, Fink A, Teplow DB. An improved method of preparing the amyloid b-protein for fibrillogenesis and neurotoxicity experiments. Amyloid 2000; 7: 166-78
85. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ. Protofibrillar intermediates of amyloid b-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999; 19: 8876-84
86. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004; 279: 46363-6
87. Necula M, Kayed R, Milton S, Glabe CG. Small molecule inhibitors of aggregation indicate that amyloid b oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 2007; 282: 10311-24
88. Nichols MR, Moss MA, Reed DK, Cratic-McDaniei S, Hoh JH, Rosenberry TL. Amyloid-beta protofibrils differ from amyloid-b aggregates induced in dilute hexafluoroisopropanol in stability and morphology. J Biol Chem 2005; 280: 2471-80
89. Smith DP, Smith DG, Curtain CC, Boas JF, Pilbrow JR, Ciccotosto GD, Lau TL, Tew DJ, Perez K, Wade JD, Bush AI, Drew SC, Separovic F, Masters CL, Cappai R, Barnham KJ. Copper-mediated amyloid-Toxicity is associated with an intermolecular histidine bridge. J Biol Chem 2005; 281: 15145-54
90. Uranga RM, Giusto NM, Salvador GA. Effect of transition metals in synaptic damage induced by amyloid b peptide. Neurosci 2010; 170: 381-9
91. Brown GC, Neher JJ. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol 2010; 41: 242-7
92. Dahlgren KN, Manelli AM, Stine WB, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-b peptides differentially affect neuronal viability. J Biol Chem 2002; 277: 32046-53
93. Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, Masters CL, Cappai R, Wade JD, Barnham KJ. Amyloid-b peptide (Ab) neurotoxicity is modulated by the rate of peptide aggregation: Ab dimers and trimers correlate with neurotoxicity. J Neurosci 2008; 28: 11950-8
94. Resende R, Ferreiro E, Pereira C, Resende De Oliveira C. Neurotoxic effect of oligomeric and fibrilar species of amyloidbeta peptide 1-42: involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. Neuroscience 2008; 155: 725-37
95. Chafekar SM, Baas F, Scheper W. Oligomer-specific Ab toxicity in cell models is mediated by selective uptake. Biochim Biophys Acta 2008; 1782: 523-31
96. Deshpande A, Mina E, Glabe C, Busciglio J. Different conformations of amyloid b induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 2006; 26: 6011-8
97. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid b-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006; 572: 477-92
98. Cleary JP. Natural oligomers of the amyloid-b protein specifically disrupt cognitive function. Nat Neurosci 2005; 8: 79-84
99. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-b protein assembly in the brain impairs memory. Nature 2006; 440: 352-7
100. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Ab1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448-53
101. Sakono M, Zako T. Amyloid oligomers: formation and toxicity of Ab oligomers. FEBS J 2010; 277: 1348-58
102. Broersen K, Rousseau F, Schymkowitz J. The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Alzheimer's Res Ther 2010; 2: 12
103. Ebenezer PJ, Weidner AM, LeVine H, Markesbery WR, Murphy MP, Zhang L, Dasuri K, Fernandez-Kim SO, Bruce-Keller AJ, Gavilán E, Keller JN. Neuron specific toxicity of oligomeric amyloid-b: role for Jun-kinase and oxidative stress. J Alzheimers Dis 2010; 22: 839-48
104. Chromy BA, Nowak RJ, Laert MP, Viola KL, Chang I, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL. Self-Assembly of Ab(1-42) into glubular neurotoxins. Biochemistry 2003; 42: 12749-60
105. Bateman TH, McLaurin J, Chakrabartty A. Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding. BMC Neurosci 2007; 8: 29
106. Mina EW, Lasagna-Reeves C, Glabe CG, Kayed R. Poloxamer 188 copolymer membrane sealant rescues toxicity of amyloid oligomers in vitro. J Mol Biol 2009; 391: 577-85
107. Chen L, Yamada K, Nabeshima T, Sokabe M. Alpha7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in b-Amyloid infused rats. Neuropharmacology 2006; 50: 254-68
108. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-b oligomers. Nature 2009; 457: 1128-32
109. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Regulation of NMDA receptor trafficking by amyloid-b. Nat Neurosci 2005; 8: 1051-8
110. Lee DH, Wang HY. Differential physiologic responses of a7 nicotinic acetylcholine receptors to b-Amyloid1-40 and b-Amyloid1-42. J Neurobiol 2003; 55: 25-30
111. Lilja AM, Porras O, Storelli E, Nordberg A, Marutle A. Functional interactions of fibrillar and oligomeric amyloid-b with a7 nicotinic receptors in Alzheimer's disease. J Alzheimers Dis 2011; 23: 335-47
112. Wang HY, Li W, Benedetti NJ, Lee DH. Alpha 7 nicotinic acetylcholine receptors mediate b-Amyloid peptide-induced tau protein phosphorylation. J Biol Chem 2003; 278: 31547-53
113. Demuro A, Parker I, Stutzmann GE. Calcium signaling and amyloid toxicity in Alzheimer's disease. J Biol Chem 2010; 285: 12463-8
114. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 2005; 280: 17294-300
115. Alberdi E, Sanchez-Gomez MV, Cavaliere F, Perez-Samartin A, Zugaza JL, Trullas R, Domercq M, Matute C. Amyloid beta oligomers induce Ca2q dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 2010; 47: 264-72
116. Yamamoto N, Matsubara E, Maeda S, Minagawa H, Takashima A, Maruyama W, Michikawa M, Yanagisawa K. A ganglioside-induced toxic soluble Ab assembly. Its enhanced formation from Ab bearing the Arctic mutation. J Biol Chem 2007; 282: 2646-55
117. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL. Amyloid b oligomers induce impairment of insulin receptors. FASEB J 2008; 22: 246-60
118. Magdesian MH, Carvalho MM, Mendes FA, Saraiva LM, Juliano MA, Juliano L, Garcia-Abreu J, Ferreira ST. Amyloidb binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/b-catenin signaling. J Biol Chem 2008; 283: 9359-68
119. Yao M, Nguyen TV, Pike CJ. b-Amyloid-induced neuronal apoptosis involves c-Jun N-Terminal kinase-dependent downregulation of Bcl-w. J Neurosci 2005; 25: 1149-58
120. St John PA. Differential binding and activation of caspase-3 in cultured hippocampal neurons by assembly forms of Ab(1-42). J Neurosci Res 2007; 85: 1205-14
121. Almeida CG, Takahashi RH, Gouras GK. b-Amyloid accumulation impairs multivesicular body sorting by ubiquitin-proteasome system. J Neurosci 2006; 26: 4277-88
122. Tseng BP, Green KN, Chan JL, Blurton-Jones M, LaFerla FM. Ab inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging 2008; 29: 1607-18
123. Chui DH, Dobo E, Makifuchi T, Akiyama H, Kawakatsu S, Petit A, Checler F, Araki W, Takahashi K, Tabira T. Apoptotic neurons in Alzheimer's disease frequently show intracellular Ab42 labeling. J Alzheimers Dis 2001; 3: 231-9
124. Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y, Wang C, Zhang H, Molkentin JD, Gunn-Moore FJ, Vonsattel JP, Arancio O, Chen JX, Yan SD. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 2008; 14: 1097-105
125. Yan SD, Fu J, Soto C, Chen X, Zhu H, Al-Mohanna F, Collison K, Zhu A, Stern E, Saido T, Tohyama M, Ogawa S, Roher A, Stern D. An intracellular protein that binds amyloid-b peptide and mediates neurotoxicity in Alzheimer's disease. Nature 1997; 389: 689-95
126. Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, Wu H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004; 304: 448-52
127. Yao J, Du H, Yan S, Fang F, Wang C, Lue LF, Guo L, Chen D, Stern DM, Gunn Moore FJ, Xi Chen J, Arancio O, Yan SS. Inhibition of amyloid-b (Ab) peptide-binding alcohol dehydrogenase-Ab interaction reduces Ab accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. J Neurosci 2011; 31: 2313-20
128. Yan SD, Shi Y, Zhu A, Fu J, Zhu H, Zhu Y, Gibson L, Stern E, Collison K, Al-Mohanna F, Ogawa S, Roher A, Clarke SG, Stern DM. Role of ERAB/L-3-hydroxyacyl-coenzyme A dehydrogenase type II activity in Ab-induced cytotoxicity. J Biol Chem 1999; 274: 2145-56
129. Mark RJ, Pang Z, Geddes JW, Uchida K, Mattson MP. Amyloid b-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci 1997; 17: 1046-54
130. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997; 68: 2092-7
131. Townsend M, Mehta T, Selkoe DJ. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 2007; 282: 33305-12
132. Tarozzi A, Morroni F, Merlicco A, Bolondi C, Teti G, Falconi M, Cantelli-Forti G, Hrelia P. Neuroprotective effects of cyanidin 3-O-glucopyranoside on amyloid b (25-35) oligomerinduced toxicity. Neurosci Lett 2010; 473: 72-6
133. Domingues A, Almeida S, da Cruz e Silva EF, Oliveira CR, Rego AC. Toxicity of b-Amyloid in HEK293 cells expressing NR1/NR2A or NR1/NR2B N-methyl-D-Aspartate receptor subunits. Neurochem Int 2007; 50: 872-80
134. Valincius G, Heinrich F, Budvytyte R, Vanderah DJ, McGillivray DJ, Sokolov Y, Hall JE, Losche M. Soluble amyloid boligomers affect dielectric membrane properties by bilayer insertion and domain formation: implications for cell toxicity. Biophys J 2009; 95: 4845-61
135. Niaura G, Budvytyte R, Kuprionis Z, Valincius G. Sum-frequency generation spectroscopy of amyloid fibrils and oligomers at air/water interface. Proc SPIE 2010; 7